Published date: Oct 04 2016

Journal Title: KnE Medicine

Issue title: The 6th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2016)

Pages: 1-6

DOI: 10.18502/kme.v1i1.529

Ade Permanawiwekobudi@yahoo.co.id

Budi Wiweko

Andon Hestiantoro

Soegiharto Soebijanto

Introduction: For decades, human chorionic gonadotropin (hCG) has been used for final oocyte maturation. It is proven to have highest life birth rate, comparing to gonadotropin releasing hormone (GnRH) agonist, but unfortunately it can increases the risk of developing ovarian hyper stimulation syndrome (OHSS). There is an ongoing debate over the optimal agent that can trigger final oocyte maturation in antagonist protocol, leading to higher IVF success rate without increasing the risk of OHSS.

Objective: To compare IVF outcomes in patient using GnRH agonist trigger and hCG for final oocyte maturation.

Method: A retrospective review of in vitro fertilization patient at Daya Medika Clinic and Yasmin Clinic.

Result: 76 women were analyzed consist of 38 women using GnRH agonist and 38 women using hCG. We found no significant differences on biochemical pregnancy rate (24.00% and 20.51%) between two group, but there were significant differences on fertilization rate (67.72% and 61.32%),  cleavage rate (95.04% and 88.92%) and blastocyst rate (13.90% and 7.38%). There was one patient developed OHSS in hCG group

Conclusion: GnRH agonists can be considered for use as a trigger final oocyte maturation in the antagonist protocol because some IVF outcomes data showed that GnRH agonists triggering were better than hCG without increasing the risk of OHSS

[1] World Health Organization. Infertility [Internet], www.who.int/topics/infertility/ en/, 2012.


[2] PERFITRI , Laporan IVF tahun, 2014, Indonesia Association for IVF, (2014).


[3] P. Humaidan, J. Quartarolo, and E. G. Papanikolaou, Preventing ovarian hyperstimulation syndrome: guidance for the clinician, Fertility and Sterility, 94, no. 2, 389–400, (2010).


[4] M. Aboulghar, Symposium: Update on prediction and management of OHSS - Prevention of OHSS, Reproductive BioMedicine Online, 19, no. 1, 33–42, (2009).


[5] P. Humaidan, Agonist trigger: What is the best approach? Agonist trigger and low dose hCG, Fertility and Sterility, 97, no. 3, 529–530, (2012).


[6] A. Delvigne and S. Rozebberg, Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Rerod Update, in Rozebberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Rerod Update, 599–77, 8, 599-77, 2002.


[7] P. Humaidan and B. Alsbjerg, GnRHa trigger for final oocyte maturation: Is HCG trigger history? Reproductive BioMedicine Online, 29, no. 3, 274–280, (2014).


[8] P. Humaidan, H. Ejdrup Bredkjær, L. G. Westergaard, and C. Yding Andersen, 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study, Fertility and Sterility, 93, no.
3, 847–854, (2010).


[9] E. Maman, Y. Yung, A. Kedem, G. M. Yerushalmi, S. Konopnicki, B. Cohen, J. Dor, and A. Hourvitz, High expression of luteinizing hormone receptors messenger RNA by human cumulus granulosa cells is in correlation with decreased fertilization, Fertility and Sterility, 97, no. 3, 592–598, (2012).


[10] T. Borgbo, B. B. Povlsen, C. Y. Andersen, R. Borup, P. Humaidan, and M. L. Grøndahl, Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger, Fertility and Sterility, 100, no. 4, 994–e2, (2013).


[11] J. D. Lamb, S. Shen, C. McCulloch, L. Jalalian, M. I. Cedars, and M. P. Rosen, Folliclestimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: A randomized, double-blind, placebo-controlled trial, Fertility and Sterility, 95, no. 5,
1655–1660, (2011).


[12] S. Kol and P. Humaidan, LH (as HCG) and FSH surges for final oocyte maturation: Sometimes it takes two to tango? Reproductive BioMedicine Online, 21, no. 5, 590– 592, (2010).


[13] S. Kol and J. Dor, Symposium: Update on prediction and management of OHSS - Opinion. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation, Reproductive BioMedicine Online, 19, no. 1, 59–60, (2009).


[14] N. Lewit, S. Kol, D. Manor, and J. Itskovitz-Eldor, Comparison of gonadotrophinreleasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: A case-control study, Human Reproduction, 11, no. 7, 1399–1402, (1996).


[15] S. Kol, Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome, Fertility and Sterility, 81, no. 1, 1–5, (2004).


[16] P. Humaidan, L. Bungum, M. Bungum, and C. Y. Andersen, Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: A pilot study, Reproductive BioMedicine Online, 13, no. 2, article no. 2315, 173–178, (2006).


[17] S. Kol and P. Humaidan, GnRH agonist triggering: Recent developments, Reproductive BioMedicine Online, 26, no. 3, 226–230, (2013).


[18] H. M. Fatemi and J. Garcia-Velasco, Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger, Fertility and Sterility, 103, no. 4, 870–873, (2015).